January 4, 2018 / 6:44 AM / a year ago

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH, Jan 4 (Reuters) - Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

The drug has received the designation for use in combination with standard immunosuppressive therapy in treating the rare blood disorder in which a patient's bone marrow fails to produce enough red blood cells, white blood cells and platelets, the Swiss drug maker said on Thursday.

Promacta is already approved as a second-line therapy in SAA, as well as for adults and children with chronic immune thrombocytopenia.

Breakthrough status is a designation given to treatments demonstrating substantial improvement over existing therapies in treating a serious or life threatening illness.

Novartis said it expects regulatory filings in both the United States and the European Union this year. (Reporting by Brenna Hughes Neghaiwi; Editing by Maria Sheahan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below